News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gilead Sciences, Inc. (GILD)'s Viread Reduces HIV Risk for Drug Users in Study



6/13/2013 7:36:08 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Gilead Sciences Inc. (GILD)’s Viread pill reduced the risk of injected-drug users contracting the AIDS virus by half in a study in Thailand, a finding that may give public health officials a new weapon to fight HIV’s spread. In a trial involving 2,413 HIV-negative drug users in Bangkok over five years, those who received Viread daily were 49 percent less likely to get infected with HIV than those who got a placebo, researchers from the Thai Ministry of Public Health and the U.S. Centers for Disease Control and Prevention reported today in the Lancet. The findings confirm the results of earlier studies that show Foster City, California-based Gilead’s Viread and Truvada can prevent infections among people at risk of catching the virus, an approach called pre-exposure prophylaxis, or PrEP. Health officials are planning pilot programs to turn the promising study into a real-world public health intervention.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at Fox News
Read at CTV.ca
Read at CBS News
Read at New York Times


comments powered by Disqus
   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES